Related references
Note: Only part of the references are listed.The role of the AR/ER ratio in ER-positive breast cancer patients
Nelson Rangel et al.
ENDOCRINE-RELATED CANCER (2018)
Prognostic value of FOXA1 in breast cancer: A systematic review and meta-analysis
Jiafeng Shou et al.
BREAST (2016)
Optimal Ki67 cut-off for luminal breast cancer prognostic evaluation: a large case series study with a long-term follow-up
Sara Bustreo et al.
BREAST CANCER RESEARCH AND TREATMENT (2016)
Clinicopathological significance of forkhead box protein A1 in breast cancer: A meta-analysis
Keli He et al.
EXPERIMENTAL AND THERAPEUTIC MEDICINE (2016)
Tailoring therapies-improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015
A. S. Coates et al.
ANNALS OF ONCOLOGY (2015)
Low FOXA1 expression predicts good response to neo-adjuvant chemotherapy resulting in good outcomes for luminal HER2-negative breast cancer cases
Y. Horimoto et al.
BRITISH JOURNAL OF CANCER (2015)
Impact of GATA-3 and FOXA1 expression in patients with hormone receptor-positive/HER2-negative breast cancer
Yuichi Hisamatsu et al.
BREAST CANCER (2015)
A simple and reproducible prognostic index in luminal ER-positive breast cancers
I. Castellano et al.
ANNALS OF ONCOLOGY (2013)
Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013
A. Goldhirsch et al.
ANNALS OF ONCOLOGY (2013)
Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Update
Antonio C. Wolff et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
FOXAI mutations in hormone-dependent cancers
Jessica L. L. Robinson et al.
FRONTIERS IN ONCOLOGY (2013)
Impact of FOXA1 Expression on the Prognosis of Patients with Hormone Receptor-Positive Breast Cancer
Yuichi Hisamatsu et al.
ANNALS OF SURGICAL ONCOLOGY (2012)
FOXA1 is an independent prognostic marker for ER-positive breast cancer
Rutika J. Mehta et al.
BREAST CANCER RESEARCH AND TREATMENT (2012)
Differential oestrogen receptor binding is associated with clinical outcome in breast cancer
Caryn S. Ross-Innes et al.
NATURE (2012)
Strategies for subtypes-dealing with the diversity of breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011
A. Goldhirsch et al.
ANNALS OF ONCOLOGY (2011)
Targeting Androgen Receptor in Estrogen Receptor-Negative Breast Cancer
Min Ni et al.
CANCER CELL (2011)
FOXA1: master of steroid receptor function in cancer
Michael A. Augello et al.
EMBO JOURNAL (2011)
Dual role of FoxA1 in androgen receptor binding to chromatin, androgen signalling and prostate cancer
Biswajyoti Sahu et al.
EMBO JOURNAL (2011)
Androgen receptor driven transcription in molecular apocrine breast cancer is mediated by FoxA1
Jessica L. L. Robinson et al.
EMBO JOURNAL (2011)
Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies
Brian D. Lehmann et al.
JOURNAL OF CLINICAL INVESTIGATION (2011)
FOXA1 is a key determinant of estrogen receptor function and endocrine response
Antoni Hurtado et al.
NATURE GENETICS (2011)
Androgen receptor expression is a significant prognostic factor in estrogen receptor positive breast cancers
Isabella Castellano et al.
BREAST CANCER RESEARCH AND TREATMENT (2010)
Expression of Forkhead- box protein A1, a marker of luminal A type breast cancer, parallels low Oncotype DX 21-gene recurrence scores
Foluso O. Ademuyiwa et al.
MODERN PATHOLOGY (2010)
Forkhead-box A1 (FOXA1) expression in breast cancer and its prognostic significance
Hany Onsy Habashy et al.
EUROPEAN JOURNAL OF CANCER (2008)
Antiproliferative actions of the synthetic androgen, mibolerone, in breast cancer cells are mediated by both androgen and progesterone receptors
Elisa J. Cops et al.
JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY (2008)
Genomic Androgen Receptor-Occupied Regions with Different Functions, Defined by Histone Acetylation, Coregulators and Transcriptional Capacity
Li Jia et al.
PLOS ONE (2008)
Forkhead box A1 expression in breast cancer is associated with luminal subtype and good prognosis
M. A. Thorat et al.
JOURNAL OF CLINICAL PATHOLOGY (2008)
A hierarchical network of transcription factors governs androgen receptor-dependent prostate cancer growth
Qianben Wang et al.
MOLECULAR CELL (2007)
FOXA1 expression in breast cancer - Correlation with luminal subtype A and survival
Sunil Badve et al.
CLINICAL CANCER RESEARCH (2007)
FOXA1: Growth inhibitor and a favorable prognostic factor in human breast cancer
Ido Wolf et al.
INTERNATIONAL JOURNAL OF CANCER (2007)
Routine assessment of prognostic factors in breast cancer using a multicore tissue microarray procedure
Anna Sapino et al.
VIRCHOWS ARCHIV (2006)
Estrogen-regulated genes predict survival in hormone receptor-positive breast cancers
DS Oh et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
BRCA1 and FOXA1 proteins coregulate the expression of the cell cycle-dependent kinase inhibitor p27Kip1
EA Williamson et al.
ONCOGENE (2006)
Regulatory mechanisms controlling human E-cadherin gene expression
YN Liu et al.
ONCOGENE (2005)
Forkhead box A1 regulates prostate ductal morphogenesis and promotes epithelial cell maturation
N Gao et al.
DEVELOPMENT (2005)
Chromosome-wide mapping of estrogen receptor binding reveals long-range regulation requiring the forkhead protein FoxA1
JS Carroll et al.
CELL (2005)
Opening of compacted chromatin by early developmental transcription factors HNF3 (FoxA) and GATA-4
LA Cirillo et al.
MOLECULAR CELL (2002)
Share Paper
